GlassScriptPhysician profile
Agustin B Mego
NPI 1831176452
$2,411.41
in general payments reported to CMS, 2019-2025
23 companies · $323 in 2025
The $323 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $325 · 2020: $102 · 2021: $154 · 2022: $300 · 2023: $781 · 2024: $427 · 2025: $323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,531.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,530.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $674.84 | 2020-2025 | Ozempic, Rybelsus, Tresiba |
| Merz North America, INC. | $517.85 | 2023 | Xeomin |
| Bard Peripheral Vascular, INC. | $231.58 | 2019 | |
| Lilly USA, LLC | $220.41 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $145.40 | 2019-2025 | Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.41 | 2025 | Jardiance |
| Astellas Pharma US INC | $64.09 | 2023-2024 | Veozah |
| Dexcom, INC. | $63.29 | 2021-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $52.42 | 2024-2025 | Krystexxa, Prolia, Evenity |
| Averitas Pharma INC. | $47.24 | 2024 | Qutenza |
| Sanofi-Aventis U.S. LLC | $44.32 | 2022-2023 | |
| Abbvie INC. | $35.80 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.96 | 2024 | |
| Smith+Nephew, INC. | $29.60 | 2025 | Grafix |
| Pfizer INC. | $28.00 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $25.29 | 2019 | |
| Ironwood Pharmaceuticals, INC | $24.26 | 2023 | Linzess |
| Phathom Pharmaceuticals, INC. | $19.95 | 2025 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $19.87 | 2024 | Zoryve |
| Abbott Laboratories | $19.05 | 2021 | |
| Amarin Pharma, INC. | $18.09 | 2020 | |
| Xeris Pharmaceuticals, INC. | $18.03 | 2023 | Gvoke Hypopen |
| Allergan, INC. | $14.66 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Agustin Mego listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.